Xylem Inc. (XYL) delivered mixed results in Q2 FY2026 on revenue of $2.3B versus the $2.3B estimate (+1.5% YoY) and EPS of $1.46. The next Xylem Inc. (XYL) earnings date is Oct 27, 2026. Below is the full Xylem Inc. earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
Xylem Inc. (XYL) Earnings Analysis — key stats
Next earnings date
Oct 27, 2026
Latest reported quarter
Q2 FY2026
Earnings verdict
Mixed
EPS beat rate
6 of last 8 (quarters above estimate)
Avg next-day move
±5.9% (over the last 8 reports)
Post-earnings direction
Up 5 / Down 3 (of the last 8 reports)
Implied move (next report)
±14.2% (options-derived · into Oct 27, 2026)
Institutional ownership
90.0% (13F as of 2026-06-30)
Top 10 holders
39.1% (of shares outstanding)
Insider activity
4 buys / 0 sells (recent Form 4 filings)
Revenue
$2.3B (vs $2.3B est · -0.2% surprise · +1.5% YoY)
EPS
$1.46 (vs $1.35 est · +8.1% surprise · +19.4% YoY)
Share price
$114.18 (+0.7%)
Market cap
$26.7B
Xylem Inc. (XYL) Earnings Analysis — beat / miss history
Quarter
Revenue
EPS
EPS surprise
Next-day move
Verdict
Q3 FY2026
$2.3B vs $2.3B est
$1.46 vs $1.35 est
+8.1%
+1.6%
Mixed
Q2 FY2026
$2.1B vs $2.1B est
$1.12 vs $1.08 est
+3.7%
-6.6%
Mixed
Q1 FY2026
$2.4B vs $2.4B est
$1.42 vs $1.41 est
+0.7%
-9.6%
In line
Q4 FY2025
$2.3B vs $2.2B est
$1.37 vs $1.23 est
+11.4%
+2.4%
Beat
Q3 FY2025
$2.3B vs $2.2B est
$1.26 vs $1.15 est
+9.6%
+8.9%
Beat
Q2 FY2025
$2.1B vs $2.0B est
$1.03 vs $0.95 est
+7.9%
+4.0%
Mixed
Q1 FY2025
$2.3B vs $2.2B est
$1.18 vs $1.13 est
+4.4%
+5.7%
Beat
Q4 FY2024
$2.1B vs $2.2B est
$1.11 vs $1.11 est
+0.0%
-8.3%
Mixed
Top institutional holders
Holder
% outstanding
Shares
Value
QoQ change
Blackrock, INC.
10.3%
25.0M
$3.0B
-2.4%
Vanguard Capital Management LLC
6.4%
15.5M
$1.8B
-1.8%
Vanguard Portfolio Management LLC
5.2%
12.6M
$1.5B
-1.2%
State Street Corp
4.7%
11.4M
$1.4B
+2.4%
Geode Capital Management, LLC
2.6%
6.3M
$747.4M
-1.0%
Amundi
2.1%
5.1M
$603.6M
-2.4%
Invesco Ltd.
2.1%
5.1M
$603.1M
+34.9%
Bank Of New York Mellon Corp
1.9%
4.7M
$552.3M
+295.1%
Royal Bank Of Canada
1.9%
4.6M
$544.4M
-3.3%
Impax Asset Management Group Plc
1.8%
4.5M
$528.3M
-2.5%
Recent insider transactions
Insider
Role
Date
Type
Shares
Value
KOCH D CHRISTIAN
director
2026-08-13
Buy
1K
$149977
KOCH D CHRISTIAN
director:
2026-08-13
Other
0
—
Johnston Joseph Patrick
officer: EVP & President, AW
2026-07-01
Other
0
—
Johnston Joseph Patrick
officer: EVP & President, AW
2026-07-01
Other
2K
$217718
Johnston Joseph Patrick
officer: EVP & President, AW
2026-07-01
Other
1K
$175444
Johnston Joseph Patrick
officer: EVP & President, AW
2026-07-01
Other
1K
$169137
Johnston Joseph Patrick
officer: EVP & President, AW
2026-07-01
Other
1K
$101494
Johnston Joseph Patrick
officer: EVP & President, AW
2026-07-01
Other
524
$45462
What you'll find
Next Xylem Inc. (XYL) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Xylem Inc. reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Xylem Inc. (XYL)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Xylem Inc.'s next earnings date?
Xylem Inc.'s (XYL) next scheduled earnings date is Oct 27, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Xylem Inc. (XYL) beat or miss earnings?
In Q2 FY2026, Xylem Inc. (XYL) posted mixed results — revenue of $2.3B versus the $2.3B estimate (-0.2% surprise) and EPS of $1.46 versus $1.35 expected (+8.1% surprise). Magnisto decodes every Xylem Inc. (XYL) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does Xylem Inc. beat earnings estimates?
Over its last 8 reported quarters, Xylem Inc. (XYL) beat Wall Street EPS estimates 6 times, most recently a mixed result in Q3 FY2026. Magnisto tracks every Xylem Inc. (XYL) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does Xylem Inc. stock move after earnings?
Over its last 8 quarterly reports, Xylem Inc. (XYL) moved an average of ±5.9% the day after earnings — ranging from -9.6% (Q1 FY2026) to +8.9% (Q3 FY2025). The stock rose after 5 of those 8 reports and fell after 3. Heading into its next report on Oct 27, 2026, options-implied volatility is pricing in a move of roughly ±14.2% (derived). Magnisto tracks the realized post-earnings move for every Xylem Inc. (XYL) quarter alongside the beat/miss verdict — past moves don't predict the next one.
Who are the largest shareholders of Xylem Inc.?
Institutions hold about 90.0% of Xylem Inc.'s (XYL) shares outstanding as of the 2026-06-30 13F quarter. Its largest institutional holders include Blackrock, INC. (10.3%), Vanguard Capital Management LLC (6.4%), Vanguard Portfolio Management LLC (5.2%). Magnisto lists Xylem Inc.'s (XYL) top 13F holders with each stake size and its quarter-over-quarter change.
Are insiders buying or selling Xylem Inc. (XYL)?
In the most recent Form 4 filings Magnisto tracks, Xylem Inc. (XYL) insiders recorded 4 purchases and 0 sales — net buying. Insider transactions are one signal among many and are often routine (option exercises or scheduled 10b5-1 sales), so Magnisto shows the raw feed for you to judge.
What is the forecast for Xylem Inc. (XYL) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Xylem Inc. (XYL), anchored to the current $114.18 share price, so you can weigh the bull, base and bear cases for Xylem Inc. side by side.
Is Xylem Inc. (XYL) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Xylem Inc. fits your own thesis and risk profile. This is research, not investment advice.